报价延迟最少15分钟:2025/11/04 02:34 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.27 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.34/-0.23
|
|
企业价值
14.61M
|
| 资产负债 |
|
每股账面净值
-0.22
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
183.00K
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/11/04 02:34 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions. |
